001065.KS KSC
JW Pharmaceutical Corporation
1W: +1.6%
1M: +0.2%
3M: +13.4%
YTD: -20.4%
1Y: -23.3%
3Y: -27.0%
5Y: -51.0%
₩22,600.00 ($16.82)
+600.00 (+2.73%)
Weekly Expected Move ±3.3%
₩21086
₩21843
₩22600
₩23357
₩24114
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Balance Sheet Trends
Total Assets
$605.3B
+0.1% ▲
5Y CAGR: +2.0%
Total Liabilities
$235.9B
-14.3% ▼
5Y CAGR: -7.1%
Shareholders Equity
$369.4B
+12.1% ▲
5Y CAGR: +12.2%
Cash & Investments
$60.3B
+85.1% ▲
5Y CAGR: +1.7%
Total Debt
$54.6B
-40.4% ▼
5Y CAGR: -21.4%
Net Debt
$15.4B
-81.1% ▼
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $33.4B | $33.9B | $15.9B | $10.4B | $39.2B |
| Short-Term Investments | $32.3B | $115.8B | $76.9B | $22.1B | $21.0B |
| Cash & ST Investments | $65.7B | $149.7B | $92.8B | $32.6B | $60.3B |
| Net Receivables | $187.6B | $147.5B | $173.6B | $155.8B | $118.2B |
| Inventory | $102.5B | $111.7B | $106.1B | $111.7B | $109.9B |
| Other Current Assets | $5.2B | $10.8B | $3.5B | $2.2B | $3.4B |
| Total Current Assets | $366.5B | $425.5B | $378.1B | $306.4B | $296.5B |
| Property, Plant & Equip. | $118.4B | $123.0B | $155.7B | $172.3B | $165.3B |
| Goodwill & Intangibles | $21.5B | $16.3B | $30.4B | $40.8B | $64.5B |
| Long-Term Investments | $69.8B | -$81.6B | $52.5B | $47.1B | $49.5B |
| Other Non-Current Assets | $36.1B | $122.9B | $7.7B | $24.4B | $9.1B |
| Total Non-Current Assets | $266.6B | $202.5B | $266.9B | $298.2B | $308.8B |
| Total Assets | $633.1B | $628.0B | $645.0B | $604.6B | $605.3B |
| — Liabilities — | |||||
| Accounts Payable | $51.6B | $82.9B | $73.8B | $59.6B | $55.9B |
| Short-Term Debt | $121.8B | $206.4B | $113.1B | $41.4B | $36.2B |
| Deferred Revenue | $72.9B | $6.7B | $0 | $0 | $8.3B |
| Other Current Liabilities | -$27.0B | $24.3B | $43.2B | $42.6B | $95.8B |
| Total Current Liabilities | $282.7B | $380.1B | $286.9B | $208.6B | $209.2B |
| Long-Term Debt | $120.7B | $0 | $30.0B | $25.1B | $0 |
| Other Non-Current Liab. | $39.8B | $18.8B | $37.2B | $18.2B | $6.2B |
| Total Non-Current Liabilities | $161.8B | $22.1B | $92.7B | $66.5B | $26.7B |
| Total Liabilities | $444.5B | $402.2B | $379.6B | $275.1B | $235.9B |
| — Equity — | |||||
| Common Stock | $53.8B | $55.4B | $57.1B | $58.2B | $59.1B |
| Retained Earnings | $58.6B | $89.1B | $92.6B | $164.1B | $192.1B |
| Accumulated OCI | $32.8B | $31.8B | $53.9B | $855M | $68.7B |
| Total Stockholders Equity | $201.2B | $240.4B | $265.4B | $329.5B | $369.4B |
| Total Liabilities & Equity | $633.1B | $628.0B | $645.0B | $604.6B | $605.3B |
| — Key Metrics — | |||||
| Total Debt | $245.1B | $209.5B | $170.3B | $91.7B | $54.6B |
| Net Debt | $211.8B | $175.6B | $154.4B | $81.3B | $15.4B |
| Total Investments | $102.1B | $34.2B | $129.4B | $69.2B | $70.5B |